

Blood Glucose Monitoring Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

Market Report | 2025-06-01 | 236 pages | Mordor Intelligence

AVAILABLE LICENSES:

- Single User License \$4750.00
- Team License (1-7 Users) \$5250.00
- Site License \$6500.00
- Corporate License \$8750.00

Report description:

Blood Glucose Monitoring Devices Market Analysis

The global blood glucose monitoring devices market is valued at USD 24.56 billion in 2025, is projected to expand at a 7.82% compound annual growth rate (CAGR), and should reach USD 35.79 billion by 2030. Growth rests on the rapid replacement of finger-stick self-monitoring with continuous and connected sensors that provide round-the-clock glycemic profiles. Asia-Pacific is emerging as the fastest-growing region as large-scale screening programmes in China and India bring first-time users into the device ecosystem. Industry leaders are forging partnerships that link glucose sensors to insulin delivery and consumer wearables, signaling a move toward full-service diabetes management platforms instead of stand-alone devices. Progress in miniaturized and non-invasive sensing is broadening the potential user base, while tighter integration of glucose data with digital therapeutics is turning real-time readings into actionable care pathways. Affordability challenges persist, yet bulk-purchase contracts and over-the-counter options are gradually lowering upfront costs, helping the market sustain momentum.

Global Blood Glucose Monitoring Devices Market Trends and Insights

Accelerating Shift from Intermittent SMBG to Continuous & Connected Glucose Monitoring

CGM adoption now outpaces self-monitoring of blood glucose (SMBG), propelled by user demand for trend data and by clinical evidence showing lower HbA1c and increased time-in-range. A new takeaway from recent real-world programmes is that non-insulin-using adults wearing factory-calibrated sensors logged 31 % fewer finger-stick tests, freeing clinical resources for

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

high-risk cases. Over-the-counter (OTC) approvals in 2024 removed prescription barriers in the United States, expanding the blood glucose monitoring market size by unlocking a mass retail channel. Device makers are simultaneously layering predictive algorithms that alert users before hypo- or hyperglycaemia, a feature that clinics increasingly view as preventive care. The upstream implication is tighter integration between CGM data flows and primary care workflows, signalling a permanent shift away from episodic testing.

Rapid Expansion of Diabetes Prevalence and Earlier Screening in Emerging Economies

Projections published in peer-reviewed literature indicate that global diabetes prevalence could rise by nearly 60% by 2025, with the steepest climb in emerging regions. Inference from recent field pilots in Southeast Asia shows that community-based HbA1c point-of-care testing (POCT) increases case detection without overburdening tertiary centres. Governments are therefore piloting bulk procurement of lower-cost strips and sensors, signalling future volume growth even at constrained unit prices. Earlier screening creates a larger pool of users who require daily glucose insight, anchoring long-term demand for both SMBG and CGM. Local device assembly in China and India is also trimming import duties, improving affordability and broadening participation in the blood glucose monitoring industry.

Persisting Affordability Gap for CGM Devices in Low-Income Segments

The American Diabetes Association notes that nearly one-third of people with diabetes forgo regular testing because supplies remain expensive. Recent price disclosures reveal a consumer sensor cost of USD 49-90 per 15-day wear, still out of reach for many uninsured patients. Fresh qualitative feedback from safety-net clinics indicates that bulk donations temporarily bridge the gap but do not address sustained access. Some payers are piloting tiered co-pays linked to HbA1c improvement targets, an innovation that could align incentives and soften out-of-pocket cost. Until such models scale, the affordability gap will continue to restrain blood glucose monitoring market share growth in lower-income communities.

Other drivers and restraints analyzed in the detailed report include:

Integration of Glucose Data into Digital Therapeutics & Remote Patient Monitoring / Miniaturization & Wearable Sensor Innovations
Enhancing User Convenience / Interoperability & Cyber-Security Concerns Hindering Device-App Data Exchange /

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Continuous glucose monitoring systems account for the fastest-expanding slice of the blood glucose monitoring market size, growing at a forecast 12.2% CAGR from 2025-2030. Evidence from randomized trials shows CGM reduces HbA1c and enhances quality-of-life metrics, which drives favorable coverage decisions. As a result, CGM encroaches on the traditional 54.8% market share that self-monitoring blood glucose devices held in 2024. Data released by two major strip manufacturers reveal flat shipment volumes, implying that test-strip demand is plateauing even in price-sensitive regions.

Integrated pump-CGM bundles now account for a rising proportion of orders among intensively managed patients, suggesting that the ecosystem approach is overtaking single-device strategies. Abbott's linkage of FreeStyle Libre sensors with Medtronic's automated delivery platform demonstrates that interoperability boosts device stickiness. Fresh procurement data indicate that hospitals adopting closed-loop systems cut inpatient hypoglycaemia alerts by double-digit rates, a performance gain that strengthens the clinical case for integration. Upcoming non-invasive technologies, such as mid-infrared optoacoustic sensing with a correlation coefficient of 0.92 to lab standards, could further disrupt incumbent shares if regulatory hurdles are cleared.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Homecare settings hold the largest blood glucose monitoring market share at 61.9 % in 2024 and are set to expand at a 10.5 % CAGR through 2030. Telehealth programmes that pair CGM data with clinician dashboards have reported sustained HbA1c reductions while cutting emergency department visits. This dynamic boosts payer interest in reimbursing home-based monitoring kits. A recent inference from subscription service enrolments shows that users who receive monthly coaching renew at higher rates, adding predictable revenue for suppliers.

Hospitals and clinics remain essential for initial device training, yet their relative growth is slower as outpatient management gains momentum. Diagnostic laboratories are pivoting toward point-of-care HbA1c testing, which demonstrated cost-utility ratios supportive of expansion into rural areas. Hybrid models that combine remote monitoring with periodic lab tests optimise workforce deployment and are attracting policy interest. Over-the-counter sensor launches further strengthen the home segment by letting consumers bypass clinic visits entirely, signalling sustained decentralisation within the blood glucose monitoring industry.

The Blood Glucose Monitoring Devices Market Report is Segmented by Device (Self-Monitoring Blood Glucose, Continuous Glucose Monitoring, and More), End User (Hospitals, and More), Patient Type (Type-1 Diabetes, and More), Modality (Invasive and Non-Invasive), Distribution Channel (Institutional Sales, and More) and Geography (North America, and More). The Market Forecasts are Provided in Terms of Value (USD) and Volume (Units).

Geography Analysis

North America commands 42% of global revenue, anchored by favourable reimbursement and early regulatory approvals for CGM. Medicare's 2023 decision to broaden coverage without finger-stick prerequisites expanded eligibility for millions of users. Fresh state-level legislation now mandates cost-sharing caps on diabetic supplies, likely sustaining unit demand. Venture funding remains robust, with capital allocations gravitating toward algorithm-enhanced platforms, ensuring the region continues to set technology benchmarks.

Asia-Pacific registers the fastest forecast CAGR at 10.2%. China's expanding community screening programmes demonstrate cost-utility outcomes that win public funding, while local assembly ventures reduce end-user prices in India, Indonesia, and Vietnam. A unique inference from recent import data indicates that mid-tier sensors are outselling low-end strips in urban Tier-2 Chinese cities, signalling a maturing customer base. Rapid smartphone penetration further supports app-centric device models, positioning the region as a hotspot for connected device uptake.

Europe maintains a strong installed base, especially in Germany, the United Kingdom, and France, where universal health systems underpin steady replacement cycles. The European Health Data Space initiative, which standardises data sharing, provides a framework that could accelerate AI-enabled glucose prediction across borders. In the Middle East & Africa, rising obesity rates and ongoing government screening campaigns in Saudi Arabia and the United Arab Emirates open new opportunities, albeit from a smaller baseline. South America, led by Brazil, shows momentum as local private insurers begin covering CGM for high-risk patients, hinting at a future expansion of blood glucose monitoring market size in the region.

List of Companies Covered in this Report:

Abbott Laboratories (Diabetes Care) / Roche / Lifescan / Dexcom / Medtronic / Ascensia / Arkray / Agamatrix Holdings / Senseonics Holdings / Bionime / Acon Laboratories / Ypsomed / Nipro / Trividia Health / Tandem Diabetes Care / Insulet / Nova Biomedical / Rossmax / Sinocare / MicroPort Life Sciences /

Additional Benefits:

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

 The market estimate (ME) sheet in Excel format /
3 months of analyst support /

Table of Contents:

1 Introduction

1.1 Study Assumptions & Market Definition

1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

4.1 Market Overview

4.2 Market Drivers

4.2.1 Accelerating Shift from Intermittent SMBG to Continuous & Connected Glucose Monitoring

4.2.2 Rapid Expansion of Diabetes Prevalence and Earlier Screening in Emerging Economies

4.2.3 Integration of Glucose Data into Digital Therapeutics & Remote Patient Monitoring

4.2.4 Miniaturization & Wearable Sensor Innovations Enhancing User Convenience

4.2.5 Strategic Collaborations Among Pharma, Med-Tech & Big Tech for End-to-End Platforms

4.2.6 Multi-payer Alignment Toward Outcomes-Based Reimbursement for Advanced Devices

4.3 Market Restraints

4.3.1 Persisting Affordability Gap for CGM Devices in Low-Income Segments

4.3.2 Interoperability & Cyber-Security Concerns Hindering Device App Data Exchange

4.3.3 Stringent Evidence Requirements for Factory-Calibrated Non-Invasive Sensors

4.3.4 Competitive Price Compression in SMBG Consumables from Generic Strip Proliferation

4.4 Value-Chain Analysis

4.5 Reimbursement Outlook

4.6 Technological Outlook

4.7 Porter's Five Forces

4.7.1 Bargaining Power of Suppliers

4.7.2 Bargaining Power of Buyers

4.7.3 Threat of New Entrants

4.7.4 Threat of Substitutes

4.7.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value, (USD) & Volume, (Units))

5.1 By Device

5.1.1 Self-Monitoring Blood Glucose

5.1.1.1 Glucometers

5.1.1.2 Test Strips

5.1.1.3 Lancets & Lancing Devices

5.1.2 Continuous Glucose Monitoring

5.1.2.1 Sensors

5.1.2.2 Transmitters & Receivers

5.1.2.3 Integrated Insulin Pump-CGM Systems

5.1.3 Non-Invasive & Emerging Technologies

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.2 By End User
 - 5.2.1 Hospitals & Clinics
 - 5.2.2 Homecare Settings
 - 5.2.3 Diagnostic Laboratories
- 5.3 By Patient Type
 - 5.3.1 Type-1 Diabetes
 - 5.3.2 Type-2 Diabetes
 - 5.3.3 Gestational & Other Types
- 5.4 By Modality
 - 5.4.1 Invasive
 - 5.4.2 Non-Invasive
- 5.5 By Distribution Channel
 - 5.5.1 Institutional Sales
 - 5.5.2 Retail Pharmacies
 - 5.5.3 Online Sales
- 5.6 Geography
 - 5.6.1 North America
 - 5.6.1.1 United States
 - 5.6.1.2 Canada
 - 5.6.1.3 Mexico
 - 5.6.2 Europe
 - 5.6.2.1 Germany
 - 5.6.2.2 United Kingdom
 - 5.6.2.3 France
 - 5.6.2.4 Italy
 - 5.6.2.5 Spain
 - 5.6.2.6 Russia
 - 5.6.2.7 Rest of Europe
 - 5.6.3 Asia-Pacific
 - 5.6.3.1 China
 - 5.6.3.2 Japan
 - 5.6.3.3 India
 - 5.6.3.4 South Korea
 - 5.6.3.5 Australia
 - 5.6.3.6 Indonesia
 - 5.6.3.7 Malaysia
 - 5.6.3.8 Thailand
 - 5.6.3.9 Vietnam
 - 5.6.3.10 Philippines
 - 5.6.3.11 Rest of Asia-Pacific
 - 5.6.4 Middle East and Africa
 - 5.6.4.1 Saudi Arabia
 - 5.6.4.2 Iran
 - 5.6.4.3 Egypt
 - 5.6.4.4 Oman
 - 5.6.4.5 South Africa
 - 5.6.4.6 Rest of Middle East and Africa

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.6.5 South America

5.6.5.1 Brazil

5.6.5.2 Argentina

5.6.5.3 Rest of South America

6 Competitive Landscape

6.1 Market Concentration

6.2 Market Share Analysis

6.3 Company Profiles (includes Global level Overview, Market level overview, Core Business Segments, Financials, Headcount, Key Information, Market Rank, Market Share, Products and Services, and analysis of Recent Developments)

6.3.1 Abbott Laboratories (Diabetes Care)

6.3.2 F. Hoffmann-La Roche Ltd

6.3.3 LifeScan Inc.

6.3.4 Dexcom Inc.

6.3.5 Medtronic plc

6.3.6 Ascensia Diabetes Care

6.3.7 ARKRAY Inc.

6.3.8 Agamatrix Holdings

6.3.9 Senseonics Holdings

6.3.10 Bionime Corporation

6.3.11 ACON Laboratories Inc.

6.3.12 Ypsomed Holding AG

6.3.13 Nipro Corporation

6.3.14 Trividia Health

6.3.15 Tandem Diabetes Care

6.3.16 Insulet Corporation

6.3.17 Nova Biomedical

6.3.18 Rossmax International Ltd

6.3.19 Sinocare Inc.

6.3.20 MicroPort Life Sciences

7 Market Opportunities & Future Outlook

7.1 White-Space & Unmet-Need Assessment

7.2 Emerging Non-Invasive Monitoring Technologies

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Blood Glucose Monitoring Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

Market Report | 2025-06-01 | 236 pages | Mordor Intelligence

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4750.00
	Team License (1-7 Users)	\$5250.00
	Site License	\$6500.00
	Corporate License	\$8750.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-04"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com